NEW YORK, NY / ACCESSWIRE / June 2, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on TapImmune Inc. (OTCQB: TPIV).
The note is available here: TPIV Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.
"We note that TPIV and the Mayo Clinic announced positive Phase 1 clinical data from the Folate Receptor Alpha trial in triple negative breast and ovarian cancer in 2H15, which demonstrated the experimental therapy was safe, well-tolerated and provided a robust immune response in 19 out of 20 patients. With three Phase 2 trials / studies commencing in 2016, we expect continued updates from the company over the next 12-24 months, including an updated on additional IND applications to the FDA, which could serve as possible catalysts for the company or the company's potential partnership discussions," stated Ajay Tandon, Chief Executive Officer of SeeThruEquity.
Additional highlights of the note are as follows:
Large market opportunity for TPIV's immunotherapy platform
The company's lead candidate, TPIV-200, is a multi-epitope peptide vaccine that targets Folate Receptor Alpha, which is overexpressed in multiple cancers including over 90% of ovarian cancer cells. TPIV's platform immunotherapy technology is initially being explored as a potential therapy for ovarian, triple-negative breast, and Her2neu cancers, though the company believes it has potential to treat a number of cancels as a standalone treatment of in combination with other approved products. Although the company is clinical-stage, we note that the potential market for its products is vast, if it receives FDA approval. According to IMS Health, the global market for cancer drugs has eclipsed $100 billion per year in sales, and the cancer immunotherapy market is one of the fastest-growing segments of this market – estimated to to reach $41 billion in major markets by 2020E, according to researchandmarkets.com.
New Phase 2 clinical study with AstraZeneca to begin at Memorial Sloan Kettering Cancer Center in 2Q16
We have been impressed by the quality of collaborative partners announced by TPIV as it commences Phase 2 clinical studies for its lead candidate, TPIV-200. Most recently, TPIV announced a new Phase 2 clinical study of TPIV-200 for ovarian cancer that will be jointly funded with major pharmaceutical corporate AstraZeneca PLC (NYSE: AZN). TPIV and AstraZeneca will supply drug in a Phase 2 clinical study of its cancer vaccine, TPIV 200, in combination with AstraZeneca's durvalumab (MEDI4736), in a single arm, study at Memorial Sloan Kettering Cancer Center, commencing in 2Q16. This development follows an announcement in 2H15 that the company's longstanding research partner the Mayo Clinic had received a $13.3mn grant from the Department of Defense to fund a 280-patient Phase 2 clinical trial of TPIV-200 for breast cancer. In addition, TapImmune will conduct a company-sponsored Phase 2 clinical study of TPIV-200 in Triple Negative Breast Cancer and file a new IND application with the FDA for HER2neu breast cancer in early 2017E. Accordingly, we expect to see significant clinical progress from TPIV during the next 24 months.
Price target of $2.25 for TPIV
TPIV continues to make substantial clinical progress, and we are impressed by the quality of partners that the company has been able to attract in its Phase 2 studies. We are updating our price target at this time for TPIV to reflect the current share count and warrants outstanding, which is higher than our original valuation. If achieved, the price target of $2.25 represents upside potential of 268.9% from the recent price of $0.61.
Please review important disclosures on our website at www.seethruequity.com.
About TapImmune Inc.
TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company's peptide or nucleic acid-based immunotherapeutics comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at http://www.tapimmune.com for details.
About SeeThruEquity
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.
For more information visit www.seethruequity.com.
Contact:
Ajay Tandon
SeeThruEquity
info@seethruequity.com
SOURCE: SeeThruEquity
ReleaseID: 440678
